Cargando…
Getting the Right Evidence After Drug Approval
To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509198/ https://www.ncbi.nlm.nih.gov/pubmed/33013409 http://dx.doi.org/10.3389/fphar.2020.569535 |
| _version_ | 1783585556953825280 |
|---|---|
| author | Vreman, Rick A. Leufkens, Hubert G. M. Kesselheim, Aaron S. |
| author_facet | Vreman, Rick A. Leufkens, Hubert G. M. Kesselheim, Aaron S. |
| author_sort | Vreman, Rick A. |
| collection | PubMed |
| description | To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan. |
| format | Online Article Text |
| id | pubmed-7509198 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75091982020-10-02 Getting the Right Evidence After Drug Approval Vreman, Rick A. Leufkens, Hubert G. M. Kesselheim, Aaron S. Front Pharmacol Pharmacology To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan. Frontiers Media S.A. 2020-09-09 /pmc/articles/PMC7509198/ /pubmed/33013409 http://dx.doi.org/10.3389/fphar.2020.569535 Text en Copyright © 2020 Vreman, Leufkens and Kesselheim http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Pharmacology Vreman, Rick A. Leufkens, Hubert G. M. Kesselheim, Aaron S. Getting the Right Evidence After Drug Approval |
| title | Getting the Right Evidence After Drug Approval |
| title_full | Getting the Right Evidence After Drug Approval |
| title_fullStr | Getting the Right Evidence After Drug Approval |
| title_full_unstemmed | Getting the Right Evidence After Drug Approval |
| title_short | Getting the Right Evidence After Drug Approval |
| title_sort | getting the right evidence after drug approval |
| topic | Pharmacology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509198/ https://www.ncbi.nlm.nih.gov/pubmed/33013409 http://dx.doi.org/10.3389/fphar.2020.569535 |
| work_keys_str_mv | AT vremanricka gettingtherightevidenceafterdrugapproval AT leufkenshubertgm gettingtherightevidenceafterdrugapproval AT kesselheimaarons gettingtherightevidenceafterdrugapproval |